Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Dec 20, 2019
Open Peer Review Period: Dec 20, 2019 - Jan 1, 2020
Date Accepted: Feb 1, 2021
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
A Novel User Utility Score for Diabetes Management Using Digital Health Technology: Results from a Randomized Controlled Trial of a Tailored Mobile Coaching System
ABSTRACT
Background:
Digital health technology has been developed to support diabetes self-management, but its effectiveness could depend on patient engagement.
Objective:
We examined the relationship between novel user utility score (UUS) developed to measure patient engagement and glycemic control among a policyholders with type 2 diabetes.
Methods:
In 72 participants, we analyzed the association of health outcomes over 12 months with UUS for the first 3 months through a sub-analysis of results from a 12-month randomized controlled trial of a tailored mobile coaching (TMC) system. The UUS was calculated as the sum of scores for four major core components (range 0–8): frequency of self-monitoring blood glucose testing, dietary and exercise records, and message reading rate.
Results:
Participants were divided into two groups: UUS:0–4 (n = 38) and UUS:5–8 (n = 34). Change from baseline in HbA1c was greater with the UUS:5–8 group than the UUS:0–4 group at 3 months (-1.0% vs. -0.37%; P = 0.018), and was sustained through 6 (-0.99 vs. -0.32; P = 0.013) and 12 months (-0.92 vs. -0.33; P = 0.049). Significant differences in changes in HbA1c between the groups were observed over the 12-month period (P for trend < 0.0001). Changes in HbA1c at 3, 6 and 12 months were significantly associated with UUS.
Conclusions:
UUS as a measure of patient engagement was associated with changes in HbA1c and could be used to predict improved glycemic control in diabetes management using a TMC system in type 2 diabetes. Clinical Trial: NCT03033407
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.